Bard's colorectal stent cleared in US:
This article was originally published in Clinica
CR Bard has received US FDA 510(k) clearance to market its Memotherm colorectal stent, for treating malignant obstructions resulting from colon cancer. Bypassing an obstruction with the self-expanding nitinol stent avoids the need for emergency surgery and allows doctors to stabilise a patient before scheduling surgery to remove a tumour, said the Murray Hill, New Jersey-based company. This eliminates the increased risks and costs associated with the traditional approach of multi-staged surgery with colostomy, it added.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.